Feeding difficulties in children with non–IgE-mediated food allergic gastrointestinal disorders
Mirna Chehade(Icahn School of Medicine at Mount Sinai), Alexia Beauregard(Wiss Janney Elstner Associates), Rosan Meyer(Imperial College London)
Cited by 55
Related Papers
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis
|New England Journal of Medicine|2022|452
Managing food allergy: GA2LEN guideline 2022
|World Allergy Organization Journal|2022|198
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age
|New England Journal of Medicine|2024|107
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet. Gastroenterology & hepatology|2023|100
Open-label, add-on trial of cetirizine for neuromyelitis optica
|Neurology Neuroimmunology & Neuroinflammation|2018|26